ProVue Lung blood test detects lung cancers with 89% overall sensitivity and 83% sensitivity at stage I, the earliest and ...
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung ...
The Study presents a novel approach to improving the global applicability of clinical trial outcomes by assessing how well results from controlled trials translate to real-world patient populations.
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that additional real-world clinical and economic data related to Nodify Lung® testing will be shared at the ...
University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help advance the treatment of lung diseases which affect men and women differently.
At 43, Shira Boehler was everything the modern health narrative celebrates: disciplined, active, a 6-mile runner, and ...
Lung cancer is, frankly, a heavyweight—it’s one of the #1 causes of cancer deaths worldwide, responsible for about 1 in 5 cancer-related deaths. Every year, more than 2 million people are diagnosed ...
Real-world lung cancer screening populations are older and sicker than those in the National Lung Screening Trial. Older age and more comorbidities may reduce the benefits of lung cancer screening.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results